Dealing with COVID-19

As travel and work restrictions are now a reality, the safety of the Patients and the Sites are of utmost importance, our Sponsors see a need to adapt and conduct their studies directly to the patient, an alternative to the scheduled site visits.

DSG is addressing this quickly changing environment going directly to the at-home patient with drug delivery and management, patient-direct randomization, self-reporting capabilities, and independent lab work.

The recently released FDA guidance on the COVID-19 outbreak suggests that “If scheduled visits at clinical sites will be significantly impacted, certain investigational products, such as those that are typically distributed for self-administration, may be amenable to alternative secure delivery methods," the full guidance can be found by clicking on the button below.